Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNT0003 after imlifidase pre-treatment in severe Crigler-Najjar syndrome with pre-existing anti-AAV8 antibodies
2023-510405-18-00Phase 2Authorised
- Sponsor
- Généthon
- Start
- Jul 2024
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GNT-0003 and imlifidase in Crigler-Najjar syndrome (CNS), sponsored by Généthon. Planned start Jul 2024; status: authorised.
02
Drugs
GNT-0003imlifidase
03
Conditions
Crigler-Najjar syndrome (CNS)
Beyond the preview
Go deeper on 2023-510405-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510405-18-00.